Medicine and Dentistry
Pediatric Acute Myeloid Leukemia
79%
Disease Modifying Therapy
58%
Fusion Gene
58%
Immune Dysregulation
58%
Gemtuzumab Ozogamicin
58%
De Novo Acute Myeloid Leukemia
58%
Pediatrics Patient
58%
Diseases
49%
T Cell
48%
Disease Surveillance
29%
Disease Management
29%
Leukemia
29%
Carcinogenesis
29%
Macrophage
19%
B Cell
19%
Acute Myeloid Leukemia
15%
Clinical Trial
10%
Recurrence Free Survival
10%
Tumor Microenvironment
9%
Plasmablast
9%
Immune Evasion
9%
Cytotoxic T-Cell
9%
Tumor Immune Microenvironment
9%
Transcriptomics
9%
Immunoglobulin Producing Cell
9%
Immunotherapy
9%
Memory B Cell
9%
Survival Rate
5%
Recurrence Risk
5%
Chemotherapy
5%
Overall Survival
5%
Pediatrics
5%
Lipocortin 5
5%
Single Nucleotide Polymorphism
5%
Immunology and Microbiology
T Cell
100%
Immunotherapy
66%
Innate Immune System
58%
Myeloid
58%
Immunosuppressive Drug
38%
Natural Killer Cell
38%
Macrophage
36%
Blood Group A Antigen
19%
Granulocyte
19%
Myeloid-Derived Suppressor Cell
19%
Lineages
19%
Neutrophil
19%
Innate Immune Cell
19%
B Cell
16%
Cytotoxic T-Cell
8%
Plasmablast
8%
Memory B Cell
8%
Transcriptomics
8%
Immunoglobulin Producing Cell
8%
Immune Evasion
8%
Neoantigen
8%
Pharmacology, Toxicology and Pharmaceutical Science
De Novo Acute Myeloid Leukemia
58%
Gemtuzumab Ozogamicin
58%
Acute Myeloid Leukemia
26%
Chemotherapy
15%
Clinical Trial
10%
Recurrence Free Survival
10%
Diseases
10%
Lipocortin 5
5%
Overall Survival
5%
Recurrence Risk
5%
Survival Rate
5%
